260 related articles for article (PubMed ID: 20818186)
1. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
[TBL] [Abstract][Full Text] [Related]
2. Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules.
Ho SY; Chen PR; Chen CH; Tsai NM; Lin YH; Lin CS; Chuang CH; Huang XF; Chan YL; Liu YK; Chung CH; Weng SL; Liao KW
J Nanobiotechnology; 2020 Apr; 18(1):58. PubMed ID: 32272948
[TBL] [Abstract][Full Text] [Related]
3. A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity.
Tseng FJ; Liu YK; Chung YS; Lin YL; Chen CH; Wang WY; Chen YC; Tsai NM; Cheng TL; Pan RY; Hu TM; Lee RP; Liao KW
Cytotechnology; 2011 May; 63(3):285-93. PubMed ID: 21461946
[TBL] [Abstract][Full Text] [Related]
4. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
5. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
Shibuya M
J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
[TBL] [Abstract][Full Text] [Related]
9. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
10. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
13. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
Liu L; Yu H; Huang X; Tan H; Li S; Luo Y; Zhang L; Jiang S; Jia H; Xiong Y; Zhang R; Huang Y; Chu CC; Tian W
BMC Cancer; 2015 Mar; 15():170. PubMed ID: 25881012
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic effect of a chemically sulfated polysaccharide from Phellinus ribis by inhibiting VEGF/VEGFR pathway.
Ding J; Jia W; Cui Y; Jin J; Zhang Y; Xu L; Liu Y
Int J Biol Macromol; 2020 Jul; 154():72-81. PubMed ID: 32171839
[TBL] [Abstract][Full Text] [Related]
16. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis.
Farzaneh Behelgardi M; Zahri S; Mashayekhi F; Mansouri K; Asghari SM
Sci Rep; 2018 Dec; 8(1):17924. PubMed ID: 30560942
[TBL] [Abstract][Full Text] [Related]
17. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
Su M; Huang J; Li J; Qin X; Tang X; Jin F; Chen S; Jiang C; Zou Z; Peng K; Nuruzzaman M; Zhang J; Luo J; Liu S; Luo Z
Oncotarget; 2016 Apr; 7(14):19018-30. PubMed ID: 26967559
[TBL] [Abstract][Full Text] [Related]
18. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
20. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
Shi J; Lu Y; Wei P
J Ethnopharmacol; 2016 Aug; 189():230-7. PubMed ID: 27224240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
